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SUMMARY 
Cytokine expression of potentially active B-cell growth factors (IL-2, IL-4, IL-6) was investigated by means of 
mRNA-expression in 29 cases of malignant non-Hodgkin B-celllymphomas. Strong signals were found for 
IL-4 and IL-6 in two and five cases, respectively, whereas the majority ofthe remaining cases did not show any 
detectable mRNA-signals for these growth factors. Comparing these results with those ofthe immunohisto-
chemistry, it could be demonstrated that at least in some ofthese cases the signalwas due to an autocrine or 
paracrine phenomenon of the tumour cells. 
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INTRODUCTION 
Normal proliferation, differentiation and activation ofhematopoietic and lymphoid cell compart-
ments are regulated by a complex network of interacting cytokines frequently produced by helper I 
inducer T -cells. Most of these extremely potent factors have been shown to have stimulatory 
effects, while others can act as downregulatory agents. Intriguing new data indicate that a cytokine 
secreted by tumour infiltrating cells or by the tumour cells themselves as an alitocrine or paracrine 
phenomenon may have antitumoural as well as growth factor activity (Biondi et al., 1989; Tepper 
et a/., 1989; Kupper et al., 1987). 
The clinical course of malignant Iymphomas shows a broad range of behaviour with respect to 
tumour growth and therapy response. Differences can be found not only between high and low-
grade malignant Iymphomas but even within the same entity with identical phenotypic properties. 
This variation in behaviour raises the question as to the influence of cytokines, which may be 
produced by infiltrating cells in a malignant Iymphoma or by the Iymphoma cells themselves. 
Since some cytokines are known to exert a strong inftuence on B-eeil proliferation and differen-
tiation (Wörmann et al., 1987; Dalkwill and Burke, 1989) we investigated a number of small 
lymphocyticand largecell (low and high grade) malignant B-celllymphomas to determine their basic 
capacity for cytokine production and possible differences between the various Iymphoma entities. 
MATERIAL AND METHODS 
Primary biopsies from 29 untreated patients with malignant Iymphomas of nodal origin were 
investigated. A portion of the lymph node was fixed in 4 per cent formaldehyde and a portion snap 
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frozen in liquid nitrogen within 1 h after biopsy. The formalin-fixed material was embedded in 
paraffin and 5 ~m paraffin sections were cut and stained for Hand E, Giemsa and PAS. Cryostat 
sections were prepared from the frozen material and immunostained with monoclonal antiborlies 
for CD2, CD3, CD5, CD19, CD22, CD23, CD25, Ki-M4 (dendritic reticulum cells) using an 
immunoperoxidase method. 
RNA preparation and Northem blotting 
Frozen tumour material was disrupted with an Ultraturrax tissuehomogenizer and suspended in a 
guanidine thiocyanate buffer (Chirgwin et al., 1979) followed by caesium-chloride gradient centri-
fugation (Glisin et al., 1974). Twenty ~g of total RNA per lane was size-fractionated by electro-
phoresis in 6 per cent formaldehyde/1·5 per cent agarose gels (Lehrach et al., 1977). Before 
RNA-transfer to nylon membranes (Hybond, Amersham), the gels were stained with ethidium 
bromide to verify equal quantities of RNA (Thomas, 1980). Equal amounts of total RNA of 
stimulated PBL (PMA 10 ng/ml Ca-ionophore-A23187 100 ng/ml) were used as contro1s. 
Hybridization 
Prehybridization was performed in 50 per cent formamide, 2 x SSC, 0·1 per cent SDS, 20 mM 
vanadyl-ribonucleoside-comp1ex, 200 ~gjml salmon sperm DNA, 200 ~gfml yeast-tRNA, 
5 x Denhardts solution, 10 per cent dextran sulfate for 4 to 6 hat 58°C. Five ng/ml ofe2JP-Iabelled 
anti-sense-cRNA probe was added and hybridization was performed for 12 to 16 h. Filters were 
washed 2 x 5 min 2 x SSC, 0·1 per cent SDS at room temperature, 2 x 30 min 2 x SSC, 0·1 per cent 
SDSat65°C, 2 x 10min0·2percent SSC,O·l percent SDS at 65°C to 70°C. Filterswereexposed to 
Kodak-X-omat fi1m (Kod~Jc, Rochester, U.S.A.) for 8 to 72 h. 
After exposure, RNA-:biots were stripped of [32]P-labelled probes by incubation in boiling 
solution of 0·1 per cent SDS and subsequent cooling to room temperature. Blots were reused 4 to 5 
tim es. 
In situ hybridiz.a~on 
Five ~m cryostate sections were placed on 2 per cent 3-(Triethoxysilyl)-propylamine (Merck) 
activated slides and· fixed in 4 per cent paraformaldehyde (Merck), 0·1 per cent glutaraldehyde 
(Merck) in PBS{pH'7·5) for 60 min at room tempeniture and stored in 70 per cent ethanol. 
Rehydrated slides wereacetylated in 0·1 percent triethanolamine (pH 8·0) (Sigma), 0·25 per cent 
acetic anhydride (Sigma}for 10 min and postfixed in 4 per cent paraforma1dehyde for 10 min, 
dehydrated in a series of graded ethanol and finally air-dried. 
Hybridization was performed in a solution containing 4 x SSC (1 x SSC=0·15 M NaCl, 0·015 M 
trisodium citrate), 10 per cent dextran sulfate (Sigma), vanadyl-ribonucleoside-complex 20 mM, 
yeast-tRNA 200 J.Lg/ml (Boehringer), salmon-sperm-DNA 200 ~g/ml (Boehringer), BSA 500 ~/ml 
(Sigma), 50 per cent deionized formamide (BRL), Tris-HCL (pH 8·0), 10 mM, EDT A 1 mM. Five 
ng e5]S (Amersham) Iabelied anti-sense or sense riboprobe were added to 20 ~1 hybridization 
solution. lncubation time was 4 to 16 hin a humidified chamber at 50°C. Washing was performed 
in 4 x SSC at room temperature for 10 min, 2 x SSC at 52°C for 30 min, 2 xSSC, 20 ~g/ml RNase A 
(Boehringer) at 3rC for 30 min, 0·2 x SSC, 10 mM DTT (Sigma) at 52°C for 30 min. Slides were 
then rinsed twice in 70 per cent ethanol, 200 mM ammonium acetate (pH 5·4) for 10 min, 
dehydrated and air-dried. 
Slides were subsequently dipped in Ilford K2 emulsion, stored for 3 days at 4°C, developed in 
Kodak D 19 developer, and Giemsa stained. 
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Probes 
The cDNA of the coding region ofiL-2 was cloned by W. Se bald and the sequence was identical to 
the published sequence of Taniguchi et al. (1983). The cDNA of the coding region of IL-4 was 
originally obtained from British Biotechnology and based on the published sequence ofYokotaet 
al. (1986). The cDNA of IL-6 was cloned by one of us (W.S.) and is identical to the published 
sequence ofHirano et al. (1986). The cDNA ofTAC, the p55 subunit ofthe IL-2 receptor, was 
cloned and sequenced by W.S. and is in accordance with the sequence published by Leonard et a/. 
(1984). 
The expected sizes of the mRNAs for IL-2, IL-4 and IL-6 are 800-900b, 700-SOOb, 1300b 
respectively and the transcript lengths for T AC are normally found to be 1500b and 3500b. The 
cDNAs of the coding regions of IL-2, IL-4, IL-6 and TAC were subcloned into transcription 
vectors (PSPT 18/19, Boehringer, F.R.G.). 
The [32P]- or [35S]-labelled sense and anti-sense-cRNA probes were generated in in vitro 
transcription experiments with T7 RNA-polymerase to a specific activity of 1 to 5 x 108 cpm/J.I.g 
cRNA (Zinn et al., 1983). 
RESULTS 
All 29 cases were classified as B-eeil Iymphomas by morphology and immunohistochemistry. 
Twenty cases were classified as low-grade and 9 cases as high-grade malignant Iymphomas. 
The exact diagnosis according to the Kiel classification (Stansfield et al., 1988) and the Working 
Formulation (non-Hodgkin's Lymphoma Pathologie Classification Project, 1982) as weil as the 
immunophenotypes and the results of cytokine mRNA expression (IL-2, IL2-R, IL-4, IL-6) are 
detailed in Table 1. Cytokine mRNA of the Iymphomas was quantified by comparison to stimu-
lated PBL (12 h/36 h) signals. The maximum signal ofPBL was quantified as + +, lower signals in 
the Iymphomas were designated as + . 
IL-2 mRNA was found at low Ievels in only two cases of centroblastic~ntrocytic Iymphoma 
(follicular mixed, small cleaved and large cell). IL2-R mRNA pattems were found in 16 cases, with 
a strong signal in one case ofhairy cellleukemia (HCL). Three cases expressed the TAC antigen in 
the tumour cells, whereas in the remaining cases expressionwas confined to the infiltrating 'host' T 
cells and macrophages as demonstrated by immunohistochemistry (CD25). In the one case ofHCL 
exhibiting a strong mRNA signal the tumour cells showed complete positivity for CD25, whereas 
in the other two cases only partial positivity was found. An IL-4 signalwas evident in only three 
cases, two ofwhich had high Ievels (BCLL-smalllymphocytic; eh-diffuse large cell), indicating 
that in these cases it was the tumour cells themselves that exhibited this autocrine expression. 
Immunohistochemistry revealed a T -cell content ofless than 3 per cent in both cases. The other two 
cases were cb/cc (follicular mixed, small cleaved and large cell) Iymphomas with a high content ofT 
cells. The remaining cases (n = 25) were completely negative for expression of IL-4 mRNA. Five 
cases (2 eh-diffuse large cell; 3 cb/cc-follicular mixed, small cleaved and large cell) bad high 
amounts of IL-6 transcripts (Figure 1 ), while all other cases were negative except for weak signals 
in one case of centrocytic Iymphoma (diffuse, small cleaved cell) and one case of B-immunoblastic 
Iymphoma. 
Four cases with clear mRNA expression in Northern blots (case no. 11, 15, 21, 24) were 
additionally investigated by in situ hybridizatiQp (Figure 2a,b). All four cases showed positive 
signals for IL-6 mRNA in 20-60 per cent ofthe whole cellular infiltrate. In immunohistochemistry 
cases no. 21 and 24 were shown to have a non-neoplastic T-cell content of less than 10 per cent 
(Table 1). 
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Table I. Detailed data of immunophenotypic properlies and mRNA 
expression in human B-eeil Iymphomas 
lnununophenotype* mRNA expressiont 
No. Diagnosis CD3 (%) CD25 IL2 IL2-R IL4 IL6 
I BCLL 5 s ++ 
2 BCLL 10 s (+) 
3 IC 5 s (+) 
4 IC 10 (+) 
5 BCLL/IC 10 s (+) 
6 HCL 25 ++ ++ 
7 HCL 25 + + 
8 cbcc 30 
9 cbcc 20 
10 cbcc 20 s (+) 
11 cbcc 15 + (+) + ++ 
12 cbcc 40 s 
13 cbcc 30 + + ++ 
14 cbcc 15 + + + 
15 cbcc 20 s 
16 cbcc 25 s (+) ++ 
17 cc 20 
18 cc 5 (+) (+) 
19 cc 10 s + 
20 cc 5 n.t. 
21 cb 10 m++ + ++ 
22 cb 5 s. ++ 
23 cb 40 
24 cb 5 m+ (+) ++ 
25 cb 10 m+ (+) 
26 cb 15 m+ + 
27 Bib 5 m+ 
28 Bib 5 (+) 
29 Bib 10 
•Immunophenotype: s: single cells (3 per cent); +: 3-10 percentpositive cells; + +: 
tumour cells positive; m: macrophages; n.t.: not tested. 
tmRNA expression: -: no expression detectable; ( + ): just detectable; +: just above 
intensity of controls; + + : within or higher intensity compared to controls. 
BCLL--<:hronic lymphocytic leukemia of 8-type; IC-immunocytoma; HCL-hairy 
cell leukemia; cb cc--amtroblasti~ntrocytic Iymphoma; cc--centrocytic Iym-
phoma; cb--centroblastic Iymphoma; 8 ib-8-immunoblastic Iymphoma. 
DISCUSSION 
The factors inftuencing the proliferation and differentiation of malignant cells are poorly under-
stood. Soluble growth factors acting in normallymphoid cell development have been suggested as 
possible candidates (Touw et a/., 1985; Wörmann et al., 1987) since malignant lymphatic cells 
are believed to originate from their normal counterparts arrested at defined stages of differen-
tiation. Growth factors might stimulate the proliferation of malignant cells without inducing 
differerttiation, thus leading to a self-sustaining growth (Greaves, 1986). 
Mediating a diverse range of biomodulatory activities on 8-cells IL-2, IL-4 and IL-6 represent 
candidate growth factors which may play an important role in the regulation of the proliferative 
activity ofmalignant B-celllymphomas (Balkwill and Burke, 19S9; Abbas, 1988). 
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Figure 1. Northern blot analysis of stimulated peripheralT cells (lane 1) and B-eeil Iymphomas (lane 2). (a) IL-
4-Iane 1: 12 h stimulation,lane 2: BCLL (case 1). (b) IL-6-lane 1: 36 h stimulation, lane 2: cb (case 21). (c) 
Tac-lane 1: 12 h stimulation, Iane 2: HCL (case 6). 
Iit·some Iymphoma celllines a dependency, an enhanced, or even an independent growth on 
exog~nous added growth factors such as IL-2, IL-4, IL-6 and GMCSF or a combination of these 
has been demonstrated (Tweeddale et al., 1989; Uchiyama et al., 1988; Yee et al., 1989; Freeman et 
a/., 1989). 
However, it must be born in mind that in vitro activities of cytokines on celllines are detected in 
artificial systems. Therefore the evaluation of cytokine-activity in malignant Iymphomas may 
provide a better insight into in vivo activities. 
Our results demonstrate that high amounts of transcripts of growth factors do indeed occur in 
some malignant Iymphomas. 
Five cases ofB-celllymphoma showed strong signals for IL-6 mRNA. Comparison with immu-
nohistochemistry demonstrated low numbers of infiltrating T cells and monocytes in these cases./n 
situ hybridization in four cases clearly demonstrated a positive IL-6 mRNA signal in 20--60 per 
cent of the infiltrating cells, two of which had a T-cell content of less than 10 per cent. lt can 
therefore be concluded that the IL-6 signal was produced at least in part by the tumour cells 
themselves. The samewas suggested by Biondi et al. (1989). Only three of our cases had transcripts 
for IL-4, with high Ievels in two cases (BCLL-small lymphocytic; eh-diffuse large cell). Two 
other cases showed weak IL-2 expression, whereas all other cases bad no detectable signals. 
Comparing the immunohistochemical results with the mRNA expression oflL-2-R (TAC), it is 
clear that the signals in some cases, especially in those wi th weak signals, were due to the infiltra ting 
T cells or histiocytes. On the other band, this comparison also demonstrates that the IL-2 receptor, 
especially in one case of HCL, was expressed by the tumour cells. 
The most striking result of this investigation is the fact that certain cases of weil defined malig-
nant B-celllymphomas expressed high amount~ of B-cell growth factors such as IL-4 or IL-6, 
whereas other cases of the same entity bad no signal for these cytokines. lt is thus provocative to 
speculate on a possible biological activity within those cases with strong signals inftuencing tumour 
proliferation and accessory cell activity. 
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(a) 
(b) 
Figure 2. (a) IL-6 mRNA expression in a high grade B-celllymphoma (case no. 2~entroblastic) detected by 
in situ hybridization with antisense IL-6 cRNA. (b) Control section treated with sense IL-6 eR NA in the same 
case. 5 Jlm cryostate sections, Giemsa stained, x 820. 
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